Titin Antibody
Also known as: TITIN AB
Use
The titin antibody test is used as a secondary diagnostic testing for myasthenia gravis when first-line diagnostic tests are negative. It is also utilized to screen for the presence of thymoma in patients with myasthenia gravis. The presence of titin antibody is associated with late onset of myasthenia gravis (MG) and carries a variable risk for thymoma. Approximately 20-40 percent of all patients with MG may test positive for titin antibody, with a higher frequency in older populations.
Special Instructions
Perform the test in a CLIA certified laboratory. The test is developed and its performance characteristics are determined by ARUP Laboratories, not cleared or approved by the US Food and Drug Administration.
Limitations
The test has not been cleared or approved by the US Food and Drug Administration, indicating that it should be used within a CLIA certified context for clinical purposes. Technical limitations include potential variability in detection frequency among different age groups, as titin antibody presence is higher in older populations.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 100371-4
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Plain Red or Serum Separator Tube (SST)
Collection Instructions
Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube.
Storage Instructions
Refrigerated. Also acceptable: Frozen
Causes for Rejection
Moderately icteric specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 1 week |
| Frozen | 1 month (avoid multiple freeze/thaw cycles) |